Expectations trend
FY2027 · fiscal year ending 2027-12-31 · fmp
Eton Pharmaceuticals, Inc. (ETON)
NASDAQHealth CareDrug Manufacturers - Specialty & GenericSnapshot 2026-11-04
$47.15-7.04%
Close 2026-11-05 · 1-day change
NASDAQHealth CareDrug Manufacturers - Specialty & GenericSnapshot 2026-11-04
The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.
Next-FY EPS estimate change · 30 days
2.10 → 2.08 EPS · FY ending Dec 31, 2027 · 2 analysts
One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.
Change in the same fiscal period’s mean EPS estimate from Oct 5, 2026 to Nov 4, 2026: (new ÷ prior − 1). Contributor count changed from 2 to 2; this is not the number of analysts revising. The ±10% axis is a display range.
The EPS and P/E reference is not available for ETON yet.
| Measure / period | Management expectations | Analyst expectations |
|---|
Management figures unavailable.
Current consensus figures unavailable.
4 published thesis conditions, with dated milestones shown separately.
| Key Factor | Why It Matters | Current Status | Break Condition | Latest Evidence |
|---|---|---|---|---|
Report at least 30% adjusted EBITDA margin in 2026 | Management targets a gross margin over 70% and adjusted EBITDA margin above 30%. | Improving | adjusted EBITDA margin falls below 20% in FY26 | Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management contextStated in 2 of 3 supplied quarters. Management reported: “We now expect to deliver an Adjusted EBITDA margin of at least 35%,” concluded Brynjelsen.” “In addition, the Company now expects to report at least a 35% Adjusted EBITDA margin, an increase from prior guidance of at least 30%.” Operating income was $12.794 million in 2026-Q2. |
Compare these dated observations with the operating requirements above
FY2027 · fiscal year ending 2027-12-31 · fmp
The evidence, the remaining questions, and what comes next
No recovery evidence is reported in the available driver assessments.
Nov 5, 2026
Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.
Observed price history; separate from operating scenarios
The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.
ETON is a high-risk growth story with recent strong financial performance, rather than an established profitable compounder. The long-term thesis is intact, supported by rapid revenue growth and higher guidance, though earnings quality remains weak because the company is loss-making.
ETON is valued at a premium to peers, with the snapshot describing its valuation as expensive. The priced-in assessment is marked justified, with no fragility warning, but the model has low confidence and points to optionality, or value tied to possible future opportunities, as a source of valuation support.
Near term, management’s 2026 revenue and adjusted EBITDA margin goals appear on track: second-quarter revenue rose 99% year over year, and guidance was raised. Adjusted gross margin improved to 73% in the second quarter, though progress toward the full-year goal is described as mixed; losses, erratic earnings surprises, and the risk of a guidance cut remain concerns.
Over the next few quarters, the thesis depends on management delivering at least $145 million in 2026 revenue and at least a 35% adjusted EBITDA margin, while sustaining gross margin above 70%. A guidance cut would be a meaningful setback; continued strength from healthcare sector peers could support the sector backdrop, while weaker job growth and rising recession fears could weigh on cyclical healthcare names.
For the 1- to 3-year view, recent execution supports an intact thesis, but the premium valuation and loss-making profile make continued delivery important. Not investment advice.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Achieve adjusted gross margin over 70% in 2026 | Management targets a gross margin over 70% and adjusted EBITDA margin above 30%. | Improving | gross margin falls below 60% in FY26 | Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management contextStated in 2 of 3 supplied quarters. Management reported: “The Company expects full year 2026 adjusted gross margin to exceed 70%, inclusive of the potential $4 million commercial milestone referred to above.” “The Company expects full year 2026 adjusted gross margin to exceed 70%.” Gross profit was $25.413 million in 2026-Q2. Delivery assessment Nov 4, 2026 |
Expand product portfolio through acquisitions | The company is expanding its product portfolio with new drug acquisitions like IMPAVIDO and HEMANGEOL. | Intact | failure to complete or integrate acquisitions by end 2026 | 2 acquisitions completed (Jul & Oct 2026) vs target by end 2026 ETON completed license agreements for ASN-001 and LIBERVANT in July and October 2026, successfully expanding its product portfolio. Nov 4, 2026Last status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management contextStated in 1 of 3 supplied quarters. Management reported: “This agreement advances our strategy of acquiring and commercializing differentiated medicines, and we are excited to work with Aquestive toward an anticipated April 2027 launch,” concluded Brynjelsen.” “In addition, we further expanded our commitment to the infantile hemangioma community with the licensing of ASN-001, an exciting late-stage development program that is expected to further improve care and broaden treatment options for families, while potentially becoming the largest revenue opportunity in our pipeline.” Delivery assessment Nov 4, 2026 |
Increase 2026 revenue to exceed $120 million | A primary condition in Eton Pharmaceuticals, Inc.'s published investment case. The stated target is >= $120 million. | Intact | revenue falls below $110 million in FY26 | Revenue: $37.589M FY2026-Q2; GAAP. Published target: >= $120 million. Annual target cannot be compared with a quarterly or TTM observation. Aug 13, 202637,589,000 USD · source valueLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management contextStated in 2 of 3 supplied quarters. Management reported: ““Given our first half performance and strong outlook for the remainder of the year, we’re pleased to again raise our annual revenue guidance and now expect at least $145 million of revenue this year.” “Guidance The Company now expects 2026 revenues to exceed $145 million, an increase from prior guidance of more than $120 million.” Revenue was $37.589 million in 2026-Q2. Delivery assessment Nov 4, 2026 |
Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.
$2.02 → $2.08 · observed estimates
$0.18B → $0.22B · observed estimates
One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.
| Snapshot | EPS | Revenue | EPS / revenue analysts |
|---|---|---|---|
| 2026-07-24 | $2.02 | $184,400,500 | 2 / 3 |
| 2026-07-25 | $2.14 | $184,400,500 | 2 / 4 |
| 2026-07-26 | $2.02 | $184,400,500 | 2 / 3 |
| 2026-07-27 | $2.02 | $184,400,500 | 2 / 3 |
| 2026-07-28 | $2.14 | $184,400,500 | 2 / 4 |
| 2026-07-29 | $2.18 | $186,925,500 | 2 / 4 |
| 2026-07-30 | $2.04 | $186,925,500 | 2 / 3 |
| 2026-07-31 | $2.18 | $186,925,500 | 2 / 4 |
| 2026-08-01 | $2.04 | $186,925,500 | 2 / 3 |
| 2026-08-02 | $2.18 | $186,925,500 | 2 / 4 |
| 2026-08-03 | $2.18 | $186,925,500 | 2 / 4 |
| 2026-08-04 | $2.18 | $186,925,500 | 2 / 4 |
| 2026-08-05 | $2.18 | $186,925,500 | 2 / 4 |
| 2026-08-06 | $2.04 | $186,925,500 | 2 / 3 |
| 2026-08-07 | $2.04 | $186,925,500 | 2 / 3 |
| 2026-08-08 | $2.18 | $186,925,500 | 2 / 4 |
| 2026-08-09 | $2.18 | $186,925,500 | 2 / 4 |
| 2026-08-10 | $2.04 | $186,925,500 | 2 / 3 |
| 2026-08-11 | $2.18 | $186,925,500 | 2 / 4 |
| 2026-08-12 | $2.18 | $186,926,250 | 2 / 4 |
| 2026-08-13 | $2.04 | $186,925,500 | 2 / 3 |
| 2026-08-14 | $2.04 | $186,925,500 | 2 / 3 |
| 2026-08-15 | $2.04 | $186,925,500 | 2 / 3 |
| 2026-08-16 | $2.04 | $186,925,500 | 2 / 3 |
| 2026-08-17 | $2.04 | $186,925,500 | 2 / 3 |
| 2026-08-18 | $2.04 | $186,925,500 | 2 / 3 |
| 2026-08-19 | $2.04 | $186,925,500 | 2 / 3 |
| 2026-08-20 | $2.04 | $186,925,500 | 2 / 3 |
| 2026-08-21 | $2.46 | $219,905,575 | 2 / 3 |
| 2026-08-22 | $2.46 | $219,905,575 | 2 / 3 |
| 2026-08-23 | $2.46 | $219,905,575 | 2 / 3 |
| 2026-08-24 | $2.46 | $219,905,575 | 2 / 3 |
| 2026-08-25 | $2.46 | $219,905,575 | 2 / 3 |
| 2026-08-26 | $2.46 | $219,905,575 | 2 / 3 |
| 2026-08-27 | $2.46 | $219,905,575 | 2 / 3 |
| 2026-08-28 | $2.46 | $219,905,575 | 2 / 3 |
| 2026-08-29 | $2.46 | $219,905,575 | 2 / 3 |
| 2026-08-30 | $2.46 | $219,905,575 | 2 / 3 |
| 2026-08-31 | $2.46 | $219,905,575 | 2 / 3 |
| 2026-09-01 | $2.46 | $219,905,575 | 2 / 3 |
| 2026-09-02 | $2.46 | $219,905,575 | 2 / 3 |
| 2026-09-03 | $2.46 | $219,905,575 | 2 / 3 |
| 2026-09-04 | $2.46 | $219,905,575 | 2 / 3 |
| 2026-09-05 | $2.46 | $219,905,575 | 2 / 3 |
| 2026-09-06 | $2.46 | $219,905,575 | 2 / 3 |
| 2026-09-07 | $2.46 | $219,905,575 | 2 / 3 |
| 2026-09-08 | $2.46 | $219,905,575 | 2 / 3 |
| 2026-09-09 | $2.46 | $219,905,575 | 2 / 3 |
| 2026-09-10 | $2.46 | $219,905,575 | 2 / 3 |
| 2026-09-11 | $2.46 | $219,905,575 | 2 / 3 |
| 2026-09-12 | $2.46 | $219,905,575 | 2 / 3 |
| 2026-09-13 | $2.10 | $219,905,575 | 2 / 3 |
| 2026-09-14 | $2.10 | $219,905,575 | 2 / 3 |
| 2026-09-15 | $2.10 | $219,905,575 | 2 / 3 |
| 2026-09-16 | $2.10 | $219,905,575 | 2 / 3 |
| 2026-09-17 | $2.10 | $219,905,575 | 2 / 3 |
| 2026-09-18 | $2.10 | $219,905,575 | 2 / 3 |
| 2026-09-19 | $2.10 | $219,905,575 | 2 / 3 |
| 2026-09-20 | $2.10 | $219,905,575 | 2 / 3 |
| 2026-09-21 | $2.10 | $219,905,575 | 2 / 3 |
| 2026-09-22 | $2.10 | $219,905,575 | 2 / 3 |
| 2026-09-23 | $2.10 | $219,905,575 | 2 / 3 |
| 2026-09-24 | $2.10 | $219,905,575 | 2 / 3 |
| 2026-09-25 | $2.10 | $219,905,575 | 2 / 3 |
| 2026-09-26 | $2.10 | $224,134,575 | 2 / 3 |
| 2026-09-27 | $2.10 | $224,134,575 | 2 / 3 |
| 2026-09-28 | $2.10 | $224,134,575 | 2 / 3 |
| 2026-09-29 | $2.10 | $224,134,575 | 2 / 3 |
| 2026-09-30 | $2.10 | $224,134,575 | 2 / 3 |
| 2026-10-01 | $2.10 | $224,134,575 | 2 / 3 |
| 2026-10-02 | $2.10 | $224,134,575 | 2 / 3 |
| 2026-10-03 | $2.10 | $219,909,575 | 2 / 3 |
| 2026-10-04 | $2.10 | $219,909,575 | 2 / 3 |
| 2026-10-05 | $2.10 | $219,909,575 | 2 / 3 |
| 2026-10-06 | $2.10 | $219,909,575 | 2 / 3 |
| 2026-10-07 | $2.10 | $219,909,575 | 2 / 3 |
| 2026-10-08 | $2.10 | $219,909,575 | 2 / 3 |
| 2026-10-09 | $2.10 | $219,909,575 | 2 / 3 |
| 2026-10-10 | $2.10 | $219,909,575 | 2 / 3 |
| 2026-10-11 | $2.10 | $219,909,575 | 2 / 3 |
| 2026-10-12 | $2.10 | $219,909,575 | 2 / 3 |
| 2026-10-13 | $2.10 | $219,909,575 | 2 / 3 |
| 2026-10-14 | $2.10 | $219,909,575 | 2 / 3 |
| 2026-10-15 | $2.18 | $219,909,575 | 2 / 3 |
| 2026-10-16 | $2.08 | $220,384,575 | 2 / 3 |
| 2026-10-17 | $2.08 | $220,384,575 | 2 / 3 |
| 2026-10-18 | $2.08 | $220,384,575 | 2 / 3 |
| 2026-10-19 | $2.08 | $220,384,575 | 2 / 3 |
| 2026-10-20 | $2.08 | $220,384,575 | 2 / 3 |
| 2026-10-21 | $2.08 | $220,384,575 | 2 / 3 |
| 2026-10-22 | $2.08 | $220,384,575 | 2 / 3 |
| 2026-10-23 | $2.08 | $220,384,575 | 2 / 3 |
| 2026-10-24 | $2.08 | $220,384,575 | 2 / 3 |
| 2026-10-25 | $2.08 | $220,384,575 | 2 / 3 |
| 2026-10-26 | $2.08 | $220,384,575 | 2 / 3 |
| 2026-10-27 | $2.08 | $220,384,575 | 2 / 3 |
| 2026-10-28 | $2.08 | $220,384,575 | 2 / 3 |
| 2026-10-29 | $2.08 | $220,384,575 | 2 / 3 |
| 2026-10-30 | $2.08 | $220,384,575 | 2 / 3 |
| 2026-10-31 | $2.08 | $220,384,575 | 2 / 3 |
| 2026-11-01 | $2.08 | $220,384,575 | 2 / 3 |
| 2026-11-02 | $2.08 | $220,384,575 | 2 / 3 |
| 2026-11-03 | $2.08 | $220,384,575 | 2 / 3 |
| 2026-11-04 | $2.08 | $220,384,575 | 2 / 3 |
Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.
Latest: 4 Buy / Strong Buy · 0 Hold · 0 Sell / Strong Sell
Recent actions · Oct 6–Nov 4 · 1 recorded
1 raises · 0 cuts · 0 unchanged · 0 without a comparable prior
Oct 6, 2026–Nov 4, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.
3 of 4 published conditions remain under pressure or need verification. The next results need to address those conditions.
The dated weekly assessment and its assumptions are available in Read detailed Outlook.